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Abstract This study was undertaken to demonstrate the unique
speci¢city of the chemokine receptor CXCR4 antagonist
AMD3100. Calcium £ux assays with selected chemokine/cell
combinations, a¡ording distinct chemokine receptor speci¢cities,
revealed no interaction of AMD3100 with any of the chemokine
receptors CXCR1 through CXCR3, or CCR1 through CCR9.
In contrast, AMD3100 potently inhibited CXCR4-mediated cal-
cium signaling and chemotaxis in a concentration-dependent
manner in di¡erent cell types. Also, AMD3100 inhibited stro-
mal cell-derived factor (SDF)-1-induced endocytosis of CXCR4,
but did not a¡ect phorbol ester-induced receptor internalization.
Importantly, AMD3100 by itself was unable to elicit intracel-
lular calcium £uxes, to induce chemotaxis, or to trigger CXCR4
internalization, indicating that the compound does not act as a
CXCR4 agonist. Speci¢c small-molecule CXCR4 antagonists
such as AMD3100 may play an important role in the treatment
of human immunode¢ciency virus infections and many other
pathological processes that are dependent on SDF-1/CXCR4
interactions (e.g. rheumatoid arthritis, atherosclerosis, asthma
and breast cancer metastasis). 2 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
In the last few years, chemokines have emerged as an im-
portant family of pro-in£ammatory cytokines, which drive a
variety of normal and pathological processes involving cell
migration. Chemokines are soluble proteins of low molecular
mass (5^15 kDa), and their nomenclature and classi¢cation is
based on the arrangement of four conserved N-terminal cys-
teine residues [1]. The two major subfamilies are the CC- (or
L-) and the CXC- (or K-) chemokines, in which the ¢rst two
cysteines are adjacent or separated by one amino acid, respec-
tively. Chemokines mediate their e¡ects by binding to speci¢c
seven transmembrane G protein-coupled receptors. CC- and
CXC-chemokines are recognized by distinct subsets of the
chemokine receptor family, termed CCR and CXCR, respec-
tively [1]. However, there exists a marked binding promiscuity
between many ligands and receptors, in that several chemo-
kines may bind to a single receptor and, vice versa, a single
chemokine may bind to several receptors. For example, the
CC-chemokine receptor 5 (CCR5) binds the CC-chemokine
ligands RANTES (regulated on activation, normal T cell ex-
pressed and secreted), MIP (macrophage in£ammatory pro-
tein)-1K and MIP-1L. On the other hand, RANTES binds to
CCR1 and CCR3, in addition to CCR5 [1]. Upon ligand
activation, chemokine receptors trigger an intracellular signal
transduction cascade comprising a transient increase in cyto-
solic free calcium [2]. Also, chemokine binding results in phos-
phorylation of the receptor protein at serine and threonine
residues in the C-terminal cytoplasmic tail, followed by rapid
receptor internalization [2].
Chemokines and their receptors mediate the recruitment of
immune cells to sites of in£ammation or infection, and, con-
sequently, are implicated in several disease states including
infectious diseases, allergy, atherosclerosis, and autoimmune
disorders such as rheumatoid arthritis, multiple sclerosis and
psoriasis [3^6]. Besides their well-known function as in£am-
matory mediators, chemokines also play an important role in
organogenesis, angiogenesis and tumor growth and metastasis
[4,7,8]. Most particularly, the CXC-chemokine/receptor pair
stromal cell-derived factor (SDF)-1/CXCR4 appears to play
a central role in allergic airway disease [9], rheumatoid arthri-
tis [10] and breast carcinoma metastasis [11]. In addition, the
chemokine receptors CCR5 and CXCR4 were identi¢ed as the
principal coreceptors, besides the CD4 receptor, for human
immunode¢ciency virus (HIV) particles to gain entry into tar-
get cells [12,13]. The so-called ‘R5’ virus strains that predom-
inantly infect macrophages by the use of CCR5 with CD4 [12]
are isolated from patients during the initial asymptomatic
stage of HIV infection, and are largely responsible for virus
transmission between individuals. The more pathogenic ‘X4’
viruses, which are typically T cell-tropic, use CXCR4 as their
coreceptor [13]. They emerge at a later stage of the disease
and cause a rapid CD4þ T cell depletion and progression
towards AIDS.
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The bicyclam AMD3100 (Fig. 1) was originally described as
a highly potent and selective inhibitor of HIV-1 and HIV-2
replication [14,15]. Only after the elucidation of the cellular
tropism of HIV by the discovery that CCR5 and CXCR4
function as HIV-1 coreceptors [12,13], the selective activity
of AMD3100 could be attributed to a speci¢c interaction of
the compound with CXCR4 but not CCR5 [16,17]. AMD3100
inhibited the intracellular calcium signaling and chemotactic
response elicited by the natural CXCR4 ligand SDF-1 in dif-
ferent cell types [16,17]. We have recently shown that
AMD3100 also e¡ectively inhibits autoimmune collagen-in-
duced arthritis in mice, by speci¢c interference with the
SDF-1-mediated migration of Mac-1þ/CXCR4þ leukocytes
towards the in£amed joints [18].
Thus, AMD3100 is an attractive drug candidate for thera-
peutic intervention in several pathologies in which CXCR4 is
critically involved. However, the speci¢city of AMD3100 for
CXCR4 has never been extensively documented. Here, we
report the inability of the compound to interfere with cell
surface (chemokine) receptors other than CXCR4. We have
also examined whether the compound on its own can generate
intracellular calcium signaling events, induce cell migration or
trigger internalization of CXCR4.
2. Materials and methods
2.1. Compounds and chemokines
The bicyclam AMD3100 was synthesized as described previously
[19]. SDF-1 and RANTES were synthesized by Dr. I. Clark-Lewis.
Interleukin (IL)-8, interferon-inducible protein-10 kDa (IP-10), eotax-
in, thymus and activation-regulated chemokine (TARC), MIP-1K,
MIP-1L, MIP-3K, MIP-3L, I309 and thymus-expressed chemokine
(TECK) were all purchased from PeproTech (London, UK).
Growth-related oncogene-K (GROK) and macrophage-derived chemo-
kine (MDC) were obtained from RpD Systems (Minneapolis, MN,
USA). Monocyte chemoattractant protein-1 (MCP-1) was obtained
from Dr. Paul Proost.
2.2. Cell lines and cell culture
CXCR4-, CCR1-, CCR3- and CCR5-transfected human astroglio-
ma U87.CD4 cells were kindly provided by Dr. Dan R. Littman
(Skirball Institute of Biomolecular Medicine, New York, NY, USA)
and were cultured in Dulbecco’s modi¢ed Eagle’s medium (Life Tech-
nologies, Paisley, UK) containing 10% heat-inactivated fetal bovine
serum (FBS) (BioWhittaker Europe, Verviers, Belgium), 0.01 M
HEPES bu¡er (Life Technologies), 0.2 mg/ml geneticin (G-418 sul-
fate) (Life Technologies) and 1 Wg/ml puromycin (Sigma-Aldrich, St.
Louis, MO, USA). CCR4-transfected human osteosarcoma HOS.CD4
cells were a kind gift from Dr. N. Landau and were maintained in
Dulbecco’s modi¢ed Eagle’s medium containing 10% FBS, 0.01 M
HEPES bu¡er and 1 Wg/ml puromycin. Human T-lymphoid SupT1,
Molt-4 and HSB-2 cells, human myeloid THP-1 cells and murine B-
lymphoblastic leukemia L1210 cells were all obtained from the Amer-
ican Type Culture Collection (Rockville, MD, USA) and were cul-
tured in RPMI-1640 medium (Life Technologies) supplemented with
10% FBS (BioWhittaker Europe) and 2 mM glutamine (Life Technol-
ogies). All cell cultures were maintained at 37‡C in a humidi¢ed, CO2-
controlled atmosphere and subcultivations were done every 2^3 days.
2.3. Isolation of primary lymphocytes and monocytes
Bu¡y coat preparations from healthy donors were obtained from
the Blood Bank in Leuven. Peripheral blood mononuclear cells
(PBMCs) were isolated by density gradient centrifugation over Lym-
phoprepTM (d=1.077 g/ml) (Nycomed, Oslo, Norway). The PBMCs
were either directly used in calcium £ux assays, or transferred to
RPMI-1640 medium supplemented with 10% FBS (BioWhittaker Eu-
rope) and 2 mM glutamine, and stimulated for 7 days with phytohe-
magglutinin (PHA) (Murex Biotech Limited, Dartford, UK) at 2 Wg/
ml and IL-2 at 10 ng/ml to obtain ‘PHA/IL-2 blasts’. Monocytes were
enriched from freshly isolated PBMCs by adherence to Petri dishes at
37‡C in RPMI-based growth medium. After 2 h, adherent cells were
washed several times at room temperature with growth medium, har-
vested by scraping with a policeman and resuspended in RPMI-based
growth medium.
2.4. Measurement of intracellular calcium mobilization
Adherent chemokine receptor-transfected U87.CD4 and HOS.CD4
cells and freshly isolated primary monocytes were seeded in 0.1%
gelatin-coated 96-well black-wall microplates (Costar, Cambridge,
MA, USA) at 2U104 cells per well for U87.CD4 and HOS.CD4 cells
and at 2U105 cells per well for primary monocytes on the day prior to
the experiment. Suspension tumor cell lines were used in stationary
growth phase (2^3 days after 2/3 subcultivation). PBMCs were used
either immediately after isolation or after a 7-day culture period in the
presence of PHA and IL-2 (PHA/IL-2 blasts). On the day of the
experiment, suspension cells and plated monolayers were loaded
with the £uorescent calcium indicator Fluo-3 acetoxymethyl (Molec-
ular Probes, Leiden, The Netherlands) at 4 WM for 45 min at room
temperature (suspension cells) or at 37‡C (adherent cells). After thor-
ough washing with calcium £ux assay bu¡er (Hanks’ balanced salt
solution with 20 mM HEPES bu¡er and 0.2% bovine serum albumin
(BSA), pH 7.4), the cells were preincubated for 15 min at 37‡C with
AMD3100 at the indicated concentrations in the same bu¡er. Then,
the intracellular calcium mobilization in response to the appropriate
chemokine was measured at 37‡C by monitoring the £uorescence as a
function of time simultaneously in all the wells using a Fluorometric
Imaging Plate Reader (FLIPR) (Molecular Devices, Sunnyvale, CA,
USA).
2.5. Antibody staining and £ow cytometry
To demonstrate the long-lasting inhibitory e¡ect of AMD3100 on
the binding of the CXCR4-speci¢c antibody 12G5 at the cell surface,
SupT1 cells were preincubated with AMD3100 at 0 or 5 Wg/ml for 30
min at room temperature in RPMI-based growth medium. Then, the
drug was washed out and the cells were further incubated at 37‡C in
drug-free growth medium. At each time point (i.e. 0, 1, 6, 24 and 48 h
after drug removal), 0.5U106 cells were washed once in cold phos-
phate-bu¡ered saline (PBS) containing 2% FBS, and were then incu-
bated for 30 min on ice with phycoerythrin-conjugated anti-CXCR4
mAb clone 12G5 (BD Pharmingen) in PBS containing 2% FBS.
Thereafter, the cells were thoroughly washed twice with PBS, ¢xed
in 1% paraformaldehyde in PBS and analyzed on a FACScalibur £ow
cytometer equipped with CellQuest software (Becton Dickinson, San
Jose, CA, USA). As a negative control for aspeci¢c background stain-
ing, the cells were stained in parallel with Simultest Isotype Control
mAb (Becton Dickinson).
2.6. Receptor internalization assay
U87.CD4 cells stably transfected with green £uorescent protein
(GFP)-coupled CXCR4 (U87.CD4.CXCR4^GFP) were seeded in
0.001% poly-D-lysine-coated 8-well Lab-Tek0 chamber slides (Nalge
Nunc International, Naperville, IL, USA) at 4U104 cells per well. The
next day, the cells were preincubated in cell culture medium with or
without 5 Wg/ml AMD3100 for 15 min at room temperature. Then,
SDF-1 or the phorbol ester, phorbol 12-myristate 13-acetate (PMA),
were added at ¢nal concentrations of 1 Wg/ml and 100 ng/ml, respec-
tively. After incubation at 37‡C for 45 min, the chamber slides were
placed on ice, the cells were washed once with ice-cold PBS, ¢xed with
1% paraformaldehyde in PBS for 5 min on ice and washed three times
with ice-cold PBS. The chambers were removed from the glass slides
Fig. 1. Chemical structure of the bicyclam AMD3100, 1,1P-[1,4-phe-
nylenebis(methylene)]-bis-1,4,8,11-azatetradecane.
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and a cover slip was placed on the cells. Cell-associated £uorescence
was examined by a Nikon £uorescence microscope.
2.7. Chemotaxis assay
SDF-1-induced cell migration was assessed using 5-Wm pore Trans-
well ¢lter membranes (Costar, Boston, MA, USA). The membrane
inserts were placed in the wells of a 24-well plate, containing 600 Wl
bu¡er (HBSS/20 mM HEPES/0.2% BSA; pH 7.4) with either no che-
mokine, 200 ng/ml SDF-1 or 25 Wg/ml AMD3100. After preincuba-
tion with AMD3100 at di¡erent concentrations (i.e. 0, 0.04, 0.2, 1, 5
or 25 Wg/ml), 1U106 freshly isolated PBMCs in 100 Wl bu¡er were
loaded into each Transwell ¢lter. The plate was then incubated at
37‡C for 2.5 h, whereafter the ¢lter inserts were carefully removed.
The migrated cells were collected from the wells and counted on a
£ow cytometer (FACScalibur, Becton Dickinson).
3. Results and discussion
3.1. AMD3100 exclusively inhibits SDF-1/CXCR4-mediated
intracellular calcium signaling
In a ¢rst set of calcium £ux experiments, we have demon-
strated the potent antagonistic activity of AMD3100 against
SDF-1/CXCR4 in di¡erent cell types. After preincubation
with AMD3100 at di¡erent concentrations, the cells were
stimulated with SDF-1 at the appropriate concentration (see
Table 1) and the changes in intracellular calcium concentra-
tion were recorded by the use of the advanced FLIPR system.
Fig. 2 clearly shows the concentration-dependent e¡ect of
AMD3100 on SDF-1-induced calcium signaling in CXCR4-
transfected human astroglioma U87.CD4 cells, freshly iso-
lated human PBMCs, CXCR4þ human T-lymphoid HSB-2
cells and murine B-lymphoblastic leukemia L1210 cells. As
CXCR4 is the sole receptor for SDF-1 [20,21], all four assay
systems allow speci¢c examination of CXCR4-mediated sig-
naling events. Table 1 displays the 50% inhibitory concentra-
tion (IC50) values of AMD3100 for inhibition of SDF-1-in-
duced calcium £ux in these and various other cell types; the
values ranged between 0.01 and 0.13 Wg/ml. Note that
AMD3100 also potently antagonized CXCR4 in the murine
L1210 cell line, the IC50 value being 0.08 Wg/ml (Fig. 2 and
Table 1). Also, intracellular calcium signaling elicited in
SupT1 cells by either the K- or the L-isoform of SDF-1 were
inhibited to the same extent by AMD3100 (data not shown).
To address the receptor speci¢city of AMD3100, we eval-
uated its ability to inhibit chemokine-induced intracellular
calcium signaling mediated by CXCR1 through CXCR3 and
CCR1 through CCR9. For each of these chemokine receptors,
we performed calcium £ux experiments with one or several
selected combinations of receptor-speci¢c chemokine ligands
and cells expressing the corresponding chemokine receptor.
Appropriate chemokine receptor expression on the particular
cell types chosen was ascertained by reverse transcription-
polymerase chain reaction and/or antibody staining and £ow
cytometry (data not shown). The di¡erent ligand/cell assay
systems a¡ording the desired receptor speci¢cities, and the
chemokine concentrations that were applied to obtain ad-
equate and reliable calcium responses, are listed in Table 1.
After preincubation with or without AMD3100 at 25 Wg/ml,
the cells were stimulated with the chemokine and the changes
in intracellular calcium concentration were recorded by the
use of the FLIPR system.
In sharp contrast to its strong antagonistic activity against
CXCR4, AMD3100 at 25 Wg/ml completely failed to block
chemokine-induced calcium signaling through CXCR1,
CXCR2, CXCR3, CCR1, CCR2, CCR3, CCR4, CCR5,
CCR6, CCR7, CCR8 and CCR9 (Table 1). For each of these
chemokine receptors, a representative calcium £ux experi-
ment, marked in the last column of Table 1, is shown in
Fig. 3. Thus, it is clear that AMD3100 speci¢cally antagonizes
CXCR4-mediated intracellular signaling without interacting
with any of the chemokine receptors CXCR1 through
CXCR3 or CCR1 through CCR9. In addition, it has been
Table 1
Overview of calcium £ux experiments performed to demonstrate the CXCR4-speci¢c antagonism by AMD3100
Chemokine receptor Ligand Concentration (ng/ml) Cell type IC50 of AMD3100 (Wg/ml) Figure
CXCR1 IL-8 500 freshly isolated PBMCs s 25 3
CXCR2 IL-8 500 freshly isolated PBMCs s 25 not shown
GROK 500 freshly isolated PBMCs s 25 3
CXCR3 IP-10 50 U87.CXCR3 s 25 not shown
200 PHA/IL-2-stimulated PBMCs s 25 3
CXCR4 SDF-1 10 U87.CD4.CXCR4 0.13 2
100 freshly isolated PBMCs 0.03 2
20 SupT1 0.04 not shown
10 THP-1 0.01 not shown
20 HSB-2 0.10 2
100 Molt-4 0.02 not shown
2.5 L1210 0.08 2
CCR1 MIP-1K 50 U87.CD4.CCR1 s 25 3
50 puri¢ed monocytes s 25 not shown
CCR2 MCP-1 50 puri¢ed monocytes s 25 3
CCR3 eotaxin 50 U87.CD4.CCR3 s 25 3
CCR4 MDC 20 HOS.CD4.CCR4 s 25 3
TARC 20 HOS.CD4.CCR4 s 25 not shown
CCR5 RANTES 5 U87.CD4.CCR5 s 25 not shown
50 puri¢ed monocytes s 25 not shown
MIP-1L 10 U87.CD4.CCR5 s 25 3
50 puri¢ed monocytes s 25 not shown
CCR6 MIP-3K 200 PHA/IL-2-stimulated PBMCs s 25 3
CCR7 MIP-3L 200 HSB-2 s 25 3
CCR8 I309 500 freshly isolated PBMCs s 25 3
CCR9 TECK 100 Molt-4 s 25 3
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previously shown that AMD3100 has no e¡ect whatsoever on
ligand activation of NK1 tachykinin (substance P) receptor,
fMLP receptor or C5a receptor [18].
To examine if AMD3100 by itself can induce calcium sig-
naling events, we triggered several cell types, including T-lym-
phoid SupT1 cells and primary human monocytes, with the
compound in the absence of any chemokine. Even at a con-
centration as high as 25 Wg/ml, AMD3100 completely failed to
elicit a detectable intracellular calcium £ux in these cells, while
SDF-1 at 500- to 1000-fold lower concentrations induced
strong calcium responses under the same experimental condi-
tions (Fig. 4).
3.2. Long-term interaction of AMD3100 with CXCR4
It has previously been reported that AMD3100 potently
blocks the binding of the anti-CXCR4 mAb 12G5 at the
cell membrane [16]. Using this feature, we have now demon-
strated that the blocking of CXCR4 by AMD3100 is a long-
lasting e¡ect. Immediately after preincubation of SupT1 cells
with AMD3100 at 5 Wg/ml, the binding of the mAb 12G5 at
the cell surface was inhibited by 85^90%, as compared to un-
treated SupT1 cells. The inhibitory e¡ect of AMD3100 re-
mained at exactly the same high level for at least 24 h after
transfer of the cells to drug-free medium (Fig. 5). At 48 h after
drug removal, the percentage of inhibition of 12G5 mAb
binding in drug-treated compared to untreated SupT1 cells
had declined to approximately 60% (Fig. 5). Such long-term
e¡ect of AMD3100 on CXCR4 points to a high-a⁄nity inter-
action between the compound and the receptor protein.
3.3. AMD3100 exclusively inhibits CXCR4-mediated host cell
entry of HIV
The highly potent and selective anti-HIV activity of
AMD3100 (IC50 : 1^10 ng/ml) against virus strains that use
CXCR4, but not CCR5, to enter their target cells, has been
described in our previous reports [14^17]. On the other hand,
Labrosse et al. demonstrated that U373MG-CD4 cells trans-
fected with the orphan receptor BOB/gpr15, the CXC-chemo-
kine receptor Bonzo/STRL33 (now designated CXCR6) or the
human cytomegalovirus-encoded CC-chemokine receptor
US28 are not protected by AMD3100 against infection with
the HIV-1 strains LAI, NDK, 89.6 and ADA and the HIV-2
strain ROD, which all can use these three chemokine recep-
tors as alternative coreceptors for cell entry [22]. Zhang et al.
also reported that AMD3100 failed to inhibit the entry of SIV
into GHOST-CD4 cells expressing BOB/gpr15, Bonzo/
STRL33, US28, GPR1, APJ or V28, indicating that
AMD3100 does not interact with any of these receptors [23].
3.4. AMD3100 speci¢cally blocks SDF-1- but not phorbol
ester-induced internalization of CXCR4
SDF-1-induced endocytosis of CXCR4, and the inhibitory
e¡ect of AMD3100 on the internalization process was visual-
6
Fig. 2. Concentration-dependent inhibition of SDF-1/CXCR4-medi-
ated intracellular calcium £ux by AMD3100 in CXCR4-transfected
human U87.CD4 cells, freshly isolated human PBMCs, human T-
lymphoid HSB-2 cells and murine B-lymphoblastic leukemia L1210
cells. After loading with the £uorescent calcium indicator Fluo-3,
the cells were preincubated for 15 min with AMD3100 at the indi-
cated concentrations, and were then stimulated with SDF-1 at the
appropriate concentration (see Table 1). The transient increase in
the intracellular calcium concentration was recorded by monitoring
the change in £uorescence of the cells as a function of time using
the FLIPR. Each data point represents the mean £uorescence of
quadruplicate microplate wells. The data of one representative ex-
periment are shown.
FEBS 26386 28-8-02
S. Hatse et al./FEBS Letters 527 (2002) 255^262258
ized by £uorescence microscopy in stably transfected
U87.CD4 cells expressing GFP-coupled CXCR4. As shown
in Fig. 6A, the £uorescent chemokine receptor was mainly
concentrated on the cell membrane in unstimulated
U87.CD4. CXCR4^GFP cells. Upon stimulation with 1 Wg/
ml SDF-1, the receptor was sequestered in endosomal vesicles
which were visible as bright spots accumulating near the nu-
cleus (Fig. 6B). Similar observations were made when the cells
were exposed to the phorbol ester PMA at 100 ng/ml (Fig.
6C). Signoret et al. have demonstrated that SDF-1 and phor-
bol esters trigger CXCR4 internalization through entirely dif-
ferent mechanistic pathways [24]. Unlike phorbol ester-in-
duced CXCR4 down-modulation, SDF-1-mediated receptor
internalization appears to be independent of protein kinase
C activation [24]. Moreover, while SDF-1 exclusively induces
CXCR4 internalization, receptor endocytosis triggered by
phorbol esters is a rather aspeci¢c process, which also implies
other cell surface receptors, such as CD4 [24]. In our experi-
ments, we found that AMD3100 prevents SDF-1- but not
PMA-induced CXCR4 internalization (Fig. 6E,F), which fur-
ther attests as to the selective antagonization of CXCR4 by
AMD3100. When the U87.CD4.CXCR4^GFP were incubated
with AMD3100 at 5 Wg/ml in the absence of SDF-1 or PMA,
the membrane localization of the CXCR4^GFP fusion protein
Fig. 3. Lack of inhibitory e¡ect of AMD3100 on chemokine-induced signaling mediated by CXCR1 through CXCR3 and CCR1 through
CCR9. Refer to Table 1 for details concerning the distinct combinations of cell types and chemokine ligands that were used to speci¢cally eval-
uate the individual receptors. After loading with the £uorescent calcium indicator Fluo-3, the cells were incubated in the presence (open circles)
or absence (closed circles) of AMD3100 at 25 Wg/ml, and were then stimulated with the appropriate chemokine (see Table 1). The transient in-
crease in the intracellular calcium concentration was recorded by monitoring the change in £uorescence of the cells as a function of time using
the FLIPR. Each data point represents the mean £uorescence of quadruplicate microplate wells. The data of one representative experiment are
shown.
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was not altered (Fig. 6D), indicating that AMD3100 by itself
cannot induce CXCR4 internalization.
3.5. Dose-dependent inhibition of SDF-1-induced chemotaxis by
AMD3100
We also examined the ability of AMD3100 to inhibit che-
mokine-induced migration of freshly isolated human PBMCs
by the use of the Transwell membrane system. SDF-1 at 200
ng/ml elicited a strong chemotactic response in PBMCs:
18.5U103 cells transmigrated across the membrane, compared
to only 2.2U103 cells in the negative control (no chemokine
added), resulting in a chemotactic index of 8.4. As shown in
Fig. 7, AMD3100 e¡ectively blocked SDF-1-induced chemo-
taxis in a dose-dependent manner. Upon pretreatment of the
cells with AMD3100 at 0.04, 0.2, 1 or 5 Wg/ml, the number of
cells that migrated in response to the chemokine was reduced
by 26, 58, 80 and 100%, respectively, yielding an IC50 value of
0.13 Wg/ml for AMD3100. In contrast, AMD3100 had no
signi¢cant e¡ect on cell migration induced by the CXCR3
ligand IP-10 (data not shown). As expected, the compound
on its own, in the absence of SDF-1, did not exhibit any
chemotactic activity. When AMD3100 was added to the lower
compartment at a concentration as high as 25 Wg/ml, the
number of migrated cells remained at the background level
(i.e. 2.6U103 cells).
3.6. Molecular interactions between AMD3100 and CXCR4
Receptor mutagenesis identi¢ed Asp171 and Asp262, located
in transmembrane domain-IV and transmembrane domain-
VI, respectively, at each end of the main ligand-binding crev-
ice of CXCR4, as essential interaction sites for AMD3100
[25,26]. It is assumed that one cyclam moiety of AMD3100
(see Fig. 1) directly interacts with the carboxylic acid group of
Asp171, and the other with Asp262. In a three-dimensional
molecular model of CXCR4, based on the crystal structure
of the prototype seven-transmembrane G protein-coupled re-
ceptor rhodopsin, AMD3100 exactly ¢ts between these two
proposed cyclam-binding sites in the binding pocket of
CXCR4 [25]. Such high-a⁄nity molecular interactions be-
tween AMD3100 and the aspartate residues at these speci¢c
positions of CXCR4 may in part explain the remarkable re-
ceptor speci¢city of the compound. Indeed, this particular
pair of aspartic acids, located at the interphase between the
transmembrane domains and the extracellular regions of the
receptor protein, appears to be highly conserved among spe-
cies. Murine, rat, feline and chimpanzee CXCR4 all have an
identical pair of aspartic acid residues at the positions corre-
sponding to 171 and 262 in human CXCR4 (Swiss-Prot li-
Fig. 4. Inability of AMD3100 to trigger intracellular calcium £uxes
in human T-lymphoid SupT1 cells and puri¢ed monocytes. The cells
were stimulated with AMD3100 at 25 Wg/ml in the absence of any
chemokine (closed circles). As a positive control, SupT1 cells and
monocytes were triggered in the same experiment with SDF-1 at 20
ng/ml and 50 ng/ml, respectively, in the absence of AMD3100 (open
circles). Each data point represents the mean £uorescence of qua-
druplicate microplate wells.
Fig. 5. Long-lasting inhibitory e¡ect of AMD3100 on the binding of the CXCR4-speci¢c mAb 12G5 at the cell surface. SupT1 cells were prein-
cubated with or without AMD3100 at 5 Wg/ml and were then transferred to drug-free growth medium. At 0, 1, 6, 24 and 48 h after drug re-
moval, the cells were stained with phycoerythrin-conjugated 12G5 mAb and analyzed by £ow cytometry. An isotype control mAb was used to
correct for aspeci¢c background staining. At 1 h after drug removal, the mean £uorescence intensities of the stained cell samples were 22 (rela-
tive units) for 12G5 mAb staining of the untreated control SupT1 cells (black histogram), 5 for 12G5 mAb staining of the SupT1 cell popula-
tion that had been pretreated with AMD3100 at 5 Wg/ml (gray histogram), and 3 for aspeci¢c background staining (white histogram). The re-
spective mean £uorescence intensity values were 35, 7 and 4 at 24 h and 25, 12 and 3 at 48 h after drug removal. The results from one
representative experiment are shown.
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brary accession numbers P70658, O08565, P56498, P56438
and P30991, respectively). This explains why AMD3100 also
inhibits SDF-1/CXCR4 interactions in the mouse (see Fig. 2),
rat and cat [18,22,27].
3.7. Conclusion
The crucial involvement of chemokine receptors, particu-
larly CXCR4, in several pathologies warrants the intense
search for potent and speci¢c receptor antagonists. In this
paper we have addressed the receptor speci¢city of the bicy-
clam AMD3100. We have shown that AMD3100 potently
inhibits CXCR4-mediated events, while showing no interac-
tion at all with any of the other (chemokine) receptors that
were evaluated. Moreover, the failure of AMD3100 to induce
intracellular calcium mobilization and cell migration, and to
trigger CXCR4 receptor internalization points to the lack of
any agonistic e¡ect of the compound. This is important with
regard to the clinical applicability of the compound, because
drug-induced chemokine receptor activation could produce
side e¡ects that may preclude its use in patients. The safety
of AMD3100 in vivo was attested in a phase I dose escalation
study with healthy volunteers [28]. Moreover, the compound
clearly showed activity against CXCR4-using HIV-1 in a
phase II clinical trial with HIV-infected persons [29]. Besides
their therapeutic potential for the treatment of HIV infections,
such highly speci¢c, small-molecule CXCR4 antagonists may
also be valuable drug candidates for the treatment of other
pathological processes driven by the SDF-1/CXCR4 interplay,
such as rheumatoid arthritis [10,18], breast cancer metastasis
[11], atherosclerosis [30] and asthma [9,31].
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